Abstract
No public abstract is available from the verified source records.
Jenifer Brown, Jonathan W. Cunningham
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
Aldosterone and cardiovascular diseases
10.1093/cvr/cvac027 · 2023
Adverse effects of aldosterone: beyond blood pressure
10.1161/jaha.123.030142 · 2024
The effect of spironolactone on morbidity and mortality in patients with severe heart failure
10.1056/nejm199909023411001 · 1999
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
10.1056/nejmoa030207 · 2003
Finerenone in heart failure with mildly reduced or preserved ejection fraction
10.1056/nejmoa2407107 · 2024
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
10.1093/eurheartj/ehab777 · 2022
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
10.1016/s0140-6736(15)00257-3 · 2015
Blood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failure
10.1093/eurheartj/ehag440 · 2026
Interaction between aldosterone and mineralocorticoid receptor antagonist: findings from the EPHESUS trial
10.1016/j.jchf.2025.02.025 · 2025
Primary aldosteronism: an Endocrine Society clinical practice guideline
10.1210/clinem/dgaf284 · 2025
Biomarkers to guide medical therapy in primary aldosteronism
10.1210/endrev/bnad024 · 2024
Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry
10.1016/j.jacc.2018.04.070 · 2018
Increasing the potassium level in patients at high risk for ventricular arrhythmias
10.1056/nejmoa2509542 · 2025
Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases
10.1210/clinem/dgae823 · 2025
Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017
10.1002/ejhf.2418 · 2022
No additional external references are available.